WallStreetZenWallStreetZen

NASDAQ: CRMD
Cormedix Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Cormedix earnings were $181.0M for the trailing 12 months ending Mar 31, 2026, with 792.3% growth year over year. The latest CRMD earnings report on Mar 31, 2026 announced Q1 2026 earnings of $38.6M, up 175.3% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, CRMD reported annual earnings of $163.1M, with -1,009.4% growth. The next CRMD earnings date is Aug 6, 2026.

CRMD past earnings growth

How has CRMD's earnings growth performed historically?

Company
792.31%
Industry
49.97%
Market
84.18%
CRMD's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
CRMD's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
CRMD's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

CRMD earnings history

Current Revenue
$400.1M
Current Earnings
$181.0M
Current Profit Margin
45.2%

CRMD Return on Equity

Current Company
50.4%
Current Industry
-141.9%
Current Market
13.5%
CRMD's Return on Equity (50.4%)... subscribe to Premium to read more.
High Return on Equity Performance

CRMD Return on Assets

Current Company
27.4%
Current Industry
-13.7%
CRMD is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when CRMD announces earnings.

CRMD Return on Capital Employed

Current Company
27.34%
Current Industry
-9.6%
CRMD has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CRMD vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
CRMD$212.72M$181.01M+792.31%$2.32
RGNX-$229.35M-$290.01MN/A-$5.60
FDMT-$152.97M-$160.90MN/A-$2.57
DNA-$219.16M-$304.39MN/A-$5.36
EIKNN/AN/AN/AN/A
View Top Biotech Stocks

CRMD earnings dates

Next earnings date
Aug 6, 2026

Cormedix Earnings Reports & History FAQ

What were Cormedix's earnings last quarter?

Cormedix (NASDAQ: CRMD) reported Q1 2026 earnings per share (EPS) of $0.48, up 50% year over year. Total CRMD earnings for the quarter were $38.60 million. In the same quarter last year, Cormedix's earnings per share (EPS) was $0.32.

If you're new to stock investing, here's how to buy Cormedix stock.

When does Cormedix report earnings?

The next CRMD earnings date is Invalid Date. Add CRMD to your watchlist to be reminded of Cormedix's next earnings date.

Is Cormedix profitable or losing money?

As of the last Cormedix earnings report, Cormedix is currently profitable. Cormedix's net profit (also called net income) for the twelve months ending Mar 31, 2026 was $181.01 million, a 953.61% increase year over year.

What was CRMD's earnings growth in the past year?

As of Cormedix's earnings date in Q3 2026, Cormedix's earnings has grown 792.31% year over year. This is 742.34 percentage points higher than the US Biotechnology industry earnings growth rate of 49.97%. CRMD earnings in the past year totalled $181.01 million.

What are Cormedix's earnings expectations?

The current EPS estimate for Cormedix's earnings report in Invalid Date is $0.26.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.